FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sylvie Negrier

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Antineoplastic Combined Chemotherapy Protocols

Anatomy

Co-author Network

Publications

TOP 3
Robert J Motzer; Sylvie Negrier; Stéphane Oudard; Connie Chen; Bernard Escudier; Martin E Gore; Subramanian Hariharan; Thomas E Hutson; Sinil Kim; M Dror Michaelson; Brad Rosbrook; Jamal Tarazi; Piotr Tomczak; Brian I Rini
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Marc Gigante; Guorong Li; Sylvie Negrier; Stephane Paul; David Perol; Jacques Tostain; An Zhao; Ellen Blanc; Bernard Escudier; Celine Ferlay; Christian Genin
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Sujata Patil; Sylvie Negrier; Michael Atkins; Ronald Bukowski; Tim Eisen; Paul Elson; Bernard Escudier; Judith Manola; Robert J Motzer
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sylvie Negrier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Robert J Motzer; Sylvie Negrier; Stéphane Oudard; Connie Chen; Bernard Escudier; Martin E Gore; Subramanian Hariharan; Thomas E Hutson; Sinil Kim; M Dror Michaelson; Brad Rosbrook; Jamal Tarazi; Piotr Tomczak; Brian I Rini
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
The lancet oncology 2013;14(6):552-62.
2012: Marc Gigante; Guorong Li; Sylvie Negrier; Stephane Paul; David Perol; Jacques Tostain; An Zhao; Ellen Blanc; Bernard Escudier; Celine Ferlay; Christian Genin
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Anticancer research 2012;32(12):5447-51.
2012: Sujata Patil; Sylvie Negrier; Michael Atkins; Ronald Bukowski; Tim Eisen; Paul Elson; Bernard Escudier; Judith Manola; Robert J Motzer
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.
The Journal of urology 2012;188(6):2095-100.
2012: S Patil; Sylvie Negrier; R A Figlin; X Huang; T E Hutson; S T Kim; M D Michaelson; Robert J Motzer
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.
British journal of cancer 2012;106(10):1587-90.
2012: Laurence Albiges; Armelle Caty; Pierre-Yves Dietrich; Brigitte Duclos; Lionel Geoffrois; Gwenaëlle Gravis; Aline Guillot; Florence Joly; Frédéric Kohser; Brigitte Laguerre; Eric Legouffe; Sylvie Negrier; Stéphane Oudard; Frédéric Rolland; Christine A Theodore; Bernard Escudier
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):482-7.
2011: Brian I Rini; Brad Rosbrook; Igor G Rusakov; Cezary Szczylik; Jamal Tarazi; Piotr Tomczak; Hirotsugu Uemura; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; David Cella; Connie Chen; Bernard Escudier; Vera A Gorbunova; Martin E Gore; Thomas E Hutson; Andrey Kaprin; Sinil Kim; Ho Yeong Lim; M Dror Michaelson; Robert J Motzer
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Lancet 2011;378(9807):1931-9.
2010: Sylvie Negrier; E Jäger; C Porta; D McDermott; M Moore; J Bellmunt; S Anderson; F Cihon; J Lewis; Bernard Escudier; R Bukowski
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Medical oncology (Northwood, London, England) 2010;27(3):899-906.
2010: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
The lancet oncology 2010;11(2):155-64.
2009: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia del Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3584-90.
2009: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3312-8.
2009: M P Sablin; Sylvie Negrier; Alain Ravaud; Stéphane Oudard; Corinne Balleyguier; J Gautier; C Celier; J Medioni; Bernard Escudier
Sequential sorafenib and sunitinib for renal cell carcinoma.
The Journal of urology 2009;182(1):29-34; discussion 34.
2009: Bernard Escudier; Cezary Szczylik; Thomas E Hutson; Tomasz Demkow; Michael Staehler; Frédéric Rolland; Sylvie Negrier; Nicole Laferriere; Urban J Scheuring; David Cella; Sonalee Shah; Ronald M Bukowski
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(8):1280-9.
2009: Nicolas Penel; Sylvie Negrier; ISABELLE RAY COQUARD; Charles Ferte; Patrick Devos; Antoine Hollebecque; Michael B Sawyer; Antoine Adenis; Pascal Seve
Development and validation of a bedside score to predict early death in cancer of unknown primary patients.
PloS one 2009;4(8):e6483.
2008: Nicolas Penel; Corinne Delcambre; Xavier Durando; Stéphanie Clisant; Mohamed Hebbar; Sylvie Negrier; Charles Fournier; Nicolas Isambert; Frédéric Mascarelli; Frédéric Mouriaux
O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.
Investigational new drugs 2008;26(6):561-5.
2008: Toni K Choueiri; Anne Plantade; Paul Elson; Sylvie Negrier; Alain Ravaud; Stéphane Oudard; Ming Zhou; Brian I Rini; Ronald M Bukowski; Bernard Escudier
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):127-31.
2007: Sylvie Negrier; David Perol; Alain Ravaud; Christine Chevreau; Jacques-Olivier Bay; Rémi Delva; Emmanuel Sevin; Armelle Caty; Bernard Escudier
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
Cancer 2007;110(11):2468-77.
2007: Robert J Motzer; Gary R Hudes; Brendan D Curti; David F McDermott; Bernard Escudier; Sylvie Negrier; Brigitte Duclos; Laurence Moore; Timothy O'Toole; Joseph P Boni; Janice P Dutcher
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3958-64.
2007: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Sorafenib in advanced clear-cell renal-cell carcinoma.
The New England journal of medicine 2007;356(2):125-34.
2007: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
The New England journal of medicine 2007;356(2):115-24.
2007: V S Bourdès; S Bonnevay; P J G Lisboa; M S H Aung; Sylvie Chabaud; Thomas Bachelot; David Perol; Sylvie Negrier
Breast cancer predictions by neural networks analysis: a comparison with logistic regression.
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 2007;2007():5424-7.
2006: Pascal Seve; ISABELLE RAY COQUARD; Véronique Trillet-Lenoir; Michael Sawyer; John Hanson; Christiane Broussolle; Sylvie Negrier; Charles Dumontet; John R Mackey
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
Cancer 2006;107(11):2698-705.
2006: Revathi Suppiah; Philip E Shaheen; Paul Elson; Seema A Misbah; Laura Wood; Robert J Motzer; Sylvie Negrier; Steven Andresen; Ronald M Bukowski
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
Cancer 2006;107(8):1793-800.
2005: Sylvie Negrier; Frédéric Gomez; Jean-Yves Douillard; Alain Ravaud; Christine Chevreau; Murielle Buclon; David Perol; Christine Lasset; Bernard Escudier
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
World journal of urology 2005;23(3):161-5.
2004: Ronald M Bukowski; Sylvie Negrier; Paul Elson
Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 2):6310S-4S.
2004: Sylvie Negrier; David Perol; Christine Menetrier-Caux; Bernard Escudier; Marc Pallardy; Alain Ravaud; Jean-Yves Douillard; Christine Chevreau; Christine Lasset; Jean-Yves Blay; Michel Pallardy
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2371-8.
2004: Christian Carrie; Sylvie Negrier; Frédéric Gomez; Philippe Thiesse; Carmine Mottolese; Didier Frappaz; Eric Bouffet
Diffuse medulla oblongata and pontine gliomas in childhood. A review of 37 cases.
Bulletin du cancer 2004;91(6):E167-83.
2003: Thierry Lesimple; Jean-Jacques Voigt; Anne Bataillard; Jean-Michel Coindre; Stéphane Culine; Alain Lortholary; Yacine Merrouche; Gérard Ganem; Marie-Christine Kaminsky; Sylvie Negrier; Maurice Perol; Pierre Bedossa; Gérard Bertrand; Roland Bugat; Karim Fizazi
[Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site].
Bulletin du cancer 2003;90(12):1071-96.
2003: Roland Bugat; Anne Bataillard; Thierry Lesimple; Jean-Jacques Voigt; Stéphane Culine; Alain Lortholary; Yacine Merrouche; Gérard Ganem; Marie-Christine Kaminsky; Sylvie Negrier; Maurice Perol; Céline Laforêt; Pierre Bedossa; Gérard Bertrand; Jean-Michel Coindre; Karim Fizazi
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002).
British journal of cancer 2003;89 Suppl 1():S59-66.
2002: Robert J Motzer; Ashok Rakhit; J Thompson; H Gurney; P Selby; R Figlin; Sylvie Negrier; S Ernst; Michael Siebels; Michelle Ginsberg; Karen Rittweger; Leon Hooftman
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(11):1799-805.
2002: Roland Bugat; Anne Bataillard; Thierry Lesimple; Jean-Jacques Voigt; Stéphane Culine; Alain Lortholary; Yacine Merrouche; Gérard Ganem; Marie-Christine Kaminsky; Sylvie Negrier; Maurice Perol; Céline Laforêt; Pierre Bedossa; Gérard Bertrand; Jean-Michel Coindre; Karim Fizazi
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site].
Bulletin du cancer 2002;89(10):869-75.
2002: Sylvie Negrier; Arnaud Mejean; Stéphane Oudard; Bernard Escudier
[Metastatic kidney cancer: new therapeutic approaches].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2002;12(4):703-8.
2002: Sylvie Negrier; Jean-Yves Douillard; Frédéric Gomez; Christine Lasset; Christine Chevreau; Bernard Escudier
[Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group].
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2002;12(2):213-8.
2000: E Voog; Yacine Merrouche; Véronique Trillet-Lenoir; Christine Lasset; P Y Peaud; Paul Rebattu; Sylvie Negrier
Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
American journal of clinical oncology 2000;23(6):614-6.
2000: Sylvie Negrier; J Maral; M Drevon; J Vinke; Bernard Escudier; Thierry Philip
Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
The cancer journal from Scientific American 2000;6 Suppl 1():S93-8.
2000: Nacilla Haicheur; Bernard Escudier; Thierry Dorval; Sylvie Negrier; P H De Mulder; J M Dupuy; D Novick; T Guillot; Stanley Wolf; P Pouillart; Wolf H Fridman; Eric Tartour
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients.
Clinical and experimental immunology 2000;119(1):28-37.
1998: Sylvie Negrier; Bernard Escudier; Christine Lasset; Jean-Yves Douillard; Jacqueline Savary; Christine Chevreau; Alain Ravaud; A Mercatello; Jean Peny; Mireille Mousseau; T Philip; T Tursz
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
The New England journal of medicine 1998;338(18):1272-8.
1997: Christine Bain; Yacine Merrouche; Isabelle Puisieux; Jean-Yves Blay; Sylvie Negrier; Valérie Bonadona; Christine Lasset; F Lanier; A Duc; Lucette Gebuhrer; Thierry Philip; Marie-Christine Favrot
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.
British journal of cancer 1997;75(2):283-6.
1997: Philippe Rougier; Roland Bugat; Jean-Yves Douillard; Stéphane Culine; E Suc; P Brunet; Y Becouarn; Marc Ychou; Michel Marty; Jean-Marc Extra; Jacques Bonneterre; Antoine Adenis; Jean-François Seitz; Gérard Ganem; Moïse Namer; Thierry Conroy; Sylvie Negrier; Yacine Merrouche; F Burki; Mireille Mousseau; P Herait; Mondher Mahjoubi
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):251-60.
1996: Eric Tartour; Jean-Yves Blay; Thierry Dorval; Bernard Escudier; Véronique Mosseri; Jean-Yves Douillard; Laurent Deneux; I Gorin; Sylvie Negrier; Claire Mathiot; Pierre Pouillart; Wolf H Fridman
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1697-703.
1995: Christian Carrie; C Mottolese; E Bouffet; Sylvie Negrier; T H Bachelot; Christine Lasset; S Helfre; J Guyotat; C L Lapras; M Brunat-Mentigny
Non-metastatic childhood ependymomas.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;36(2):101-6.
1995: Yacine Merrouche; Sylvie Negrier; C Bain; Valérie Combaret; A Mercatello; B Coronel; JF Moskovtchenko; P Tolstoshev; R Moen; T Philip
Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):410-8.
1994: Christian Carrie; N Breteau; Sylvie Negrier; D Frappaz; E Bouffet; Philippe Thiesse; Jean-Yves Blay; M Clavel; T Philip; P Biron
The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report.
Medical and pediatric oncology 1994;22(5):355-7.
1993: T Philip; Sylvie Negrier; Christine Lasset; B Coronel; Monique Bret; Jean-Yves Blay; Yacine Merrouche; Christian Carrie; P Kaemmerlen; F Chauvin
Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
British journal of cancer 1993;68(5):1036-42.
1993: Christine Lasset; Yacine Merrouche; Sylvie Negrier; Paul Rebattu; J Berille; J P Bizzari; F Chauvin; T Philip
Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma.
Cancer chemotherapy and pharmacology 1993;32(4):329-31.
1993: P A Palmer; Jens Atzpodien; T Philip; Sylvie Negrier; Holger Kirchner; H Von der Maase; Poul F Geertsen; P Evers; E Loriaux; R Oskam
A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma.
Cancer biotherapy 1993;8(2):123-36.
1992: Jean-Yves Blay; Sylvie Negrier; Valérie Combaret; S Attali; E Goillot; Yacine Merrouche; A Mercatello; A Ravault; J M Tourani; JF Moskovtchenko
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Cancer research 1992;52(12):3317-22.
1992: P A Palmer; J Vinke; T Philip; Sylvie Negrier; Jens Atzpodien; Holger Kirchner; R Oskam; C R Franks
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(6):475-80.
1992: Sylvie Negrier; A Mercatello; B Coronel; Alain Ravaud; Yacine Merrouche; Monique Bret; F Lanier; JF Moskovtchenko; T Philip
[Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience].
Journal de chirurgie 1992;129(6-7):292-6.
1992: Sylvie Negrier; A Mercatello; T Philip
[Treatment of renal cancer in adults with interleukin 2].
La Revue du praticien 1992;42(10):1241-5.
1991: Alain Ravaud; Sylvie Negrier; Fabrice Lakdja; A Mercatello; Laurent Cany; B Coronel; J Y Ranchere; Yves Bécouarn; Binh Nguyen Bui; T Philip
[Adverse effects of interleukin 2].
Bulletin du cancer 1991;78(11):989-1005.
1991: Sylvie Negrier; J Y Ranchere; I Philip; Yacine Merrouche; P Biron; Didier Blaise; Michel Attal; Paul Rebattu; M Clavel; C Pourreau
Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
Bone marrow transplantation 1991;8(4):259-64.
1991: Sylvie Negrier; J Michon; D Floret; E Bouffet; J C Gentet; I Philip; P Cochat; D Stamm; J Costil; M Gaspard
Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1363-70.
1990: Jean-Yves Blay; Marie-Christine Favrot; Sylvie Negrier; Valérie Combaret; S Chouaib; A Mercatello; P Kaemmerlen; C R Franks; T Philip
Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.
Cancer research 1990;50(8):2371-4.
1990: Marie-Christine Favrot; Valérie Combaret; Sylvie Negrier; I Philip; Philippe Thiesse; C Freydel; J T Bijmann; C R Franks; A Mercatello; T Philip
Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Journal of biological response modifiers 1990;9(2):167-77.
1990: Marie-Christine Favrot; Carole Coze; Valérie Combaret; M Gaspard; C Colin; C Franks; Sylvie Negrier; I Philip; T Philip
Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
Molecular biotherapy 1990;2(1):32-7.
1990: Marie-Christine Favrot; J Michon; D Floret; C Cochat; Sylvie Negrier; Claire Mathiot; Carole Coze; J M Zucker; C R Franks; E Bouffet
Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation.
Pediatric hematology and oncology 1990;7(3):275-84.
1990: I Yaniv; E Bouffet; C Irle; Sylvie Negrier; P Biron; Marie-Christine Favrot; I Philip; M Brunat-Mentigny; T Philip
Autologous bone marrow transplantation in pediatric solid tumors.
Pediatric hematology and oncology 1990;7(1):35-46.
1989: Marie-Christine Favrot; D Floret; Sylvie Negrier; P Cochat; E Bouffet; D C Zhou; C R Franks; T Bijman; M Brunat-Mentigny; I Philip
Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
Bone marrow transplantation 1989;4(5):499-503.
1989: Marie-Christine Favrot; Carole Coze; Valérie Combaret; I Philip; T Philip; M Gaspard; Sylvie Negrier; C R Franks
Correspondence re: John R. Yanelli et al., Enhancement of Human Lymphokine-activated Killer Cell Cytolysis and a Method for Increasing Lymphokine-activated Killer Cell Yields to Cancer Patients. Cancer Res., 48: 5696-5700, 1988.
Cancer research 1989;49(15):4369.
1989: T Philip; A Mercatello; Sylvie Negrier; I Philip; Paul Rebattu; P Kaemmerlin; M Gaspard; E Tognier; Valérie Combaret; J T Bijmann
Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.
Cancer treatment reviews 1989;16 Suppl A():91-104.
1989: Marie-Christine Favrot; D Floret; J Michon; Sylvie Negrier; E Bouffet; Carole Coze; M Gaspard; P Cochat; Philippe Thiesse; G Andreu
A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.
Cancer treatment reviews 1989;16 Suppl A():129-42.
1989: Marie-Christine Favrot; Sylvie Negrier; Valérie Combaret; T Philip
[Cytokines and their receptors networks: biology and therapeutic possibilities].
Pédiatrie 1989;44(7):531-8.